DFTX Definium Therapeutics, Inc.
$30.16
Definium Therapeutics, Inc. (DFTX) Earnings News
Earnings press releases, previews and reviews for Definium Therapeutics, Inc. (DFTX), newest first. Our most recent is review: Definium Beats on a Warrant-Aided Loss as Two More Phase 3 Wins De-Risk DT120, but the Stock Still Sits Near Its Quarter Lows.
Monday
November 9, 2026
6:47 PM ET
Definium Beats on a Warrant-Aided Loss as Two More Phase 3 Wins De-Risk DT120, but the Stock Still Sits Near Its Quarter Lows
Earnings Whispers · Review
Monday
November 9, 2026
4:01 PM ET
Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
Monday
November 2, 2026
6:32 PM ET
Definium's Q3 Report Must Show GAD Data Answers and Commercial Discipline After 21% Slide
Earnings Whispers · Preview
Thursday
October 29, 2026
4:01 PM ET
Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
Thursday
August 6, 2026
4:01 PM ET
Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Thursday
July 30, 2026
4:01 PM ET
Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026